Rapid confirmation of HIV infection  by Constantine, Niel T. & Ketema, Fassil
Original Report 
Rapid confirmation of HIV infection 
Niel T. Constantine(l) and Fassil Ketema(l) 
Objective: To investigate the utility of a prototype rapid confirmatory HIV assay which offers specific results in 5 
min and has applications in a variety of important testing situations. 
Methods: The performance of the rapid confirmatory assay was assessed with 849 blood samples, including serum, 
plasma, venipuncture whole blood, and peripheral blood collected via fingerstick. Included were over 700 HIV 
Western blot (WB)-confirmed antibody positive sera, and others which were classified as negative or indeterminate 
by WB. The analytic sensitivity of the rapid confirmatory assay was assessed using 13 HIV-l seroconversion panels, 
and all results were compared to those of an FDA-licensed WB reference test. 
Results: The rapid test exhibited 100% concordance with the reference test when testing HIV-l WB-confirmed 
positive samples, and 92.3 % concordance with samples having WB-inconclusive results. The sensitivity for confirming 
recent seroconversion was as good, or better than, the FDA-licensed HIV-l WB in lo/13 panels. The rapid assay 
performed accurately with whole blood collected from fingerstick, and exhibited excellent precision and repro- 
ducibility. 
Conclusion: We conclude that this rapid HIV confirmatory assay, the first of its kind, demonstrates proof of principle 
for the accurate confirmation of HIV-l infection and offers important advantages in public health and clinical testing 
venues. 
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INTRODUCTION 
Since their introduction in the late 1980s rapid HIV 
assays have gained respect because of their continual 
improvement and attractive features, as exemplified by 
the FDA licensure of a rapid HIV test in the USA’ and 
a number of approved rapid HIV tests in Europe.2 In 
addition to their use in laboratories which possess less 
than optimal infrastructure (e.g. unstable electricity), they 
have found applications as components of alternative 
HIV confirmatory strategies3 in occupational exposure 
cases4 and for women in labor,5 where results can be 
provided in a clinically relevant time frame to decrease 
transmission. More recently, rapid tests have been shown 
to offer important advantages in US public health clinics, 
where a large number of clients do not return for results.6 
In such clinics, over 700 000 individuals, including over 
1000 HIV-infected person who did not return to receive 
their results, would have been informed and counseled 
had rapid tests been used. This has important implica- 
tions for providing intervention strategies to decrease 
transmission and for enhancing the quality of life in 
infected individuals. Although the use of rapid screening 
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assays allows for immediate counseling of HIV-negative 
individuals, persons having reactive screening results 
would still be required to return for supplemental test- 
ing. Also, persons are inappropriately given anti-HIV 
therapy based on reactive results from screening tests of 
source patients in occupational exposure cases and 
from women in labor, because results are later found 
to be false positives (N. T. Constantine, unpublished 
observations). The immediate availability of confirma- 
tory results would provide for more effective testing, 
counseling, and treatment. 
As with all HIV serologic screening strategies, rapid 
HIV assays produce a certain proportion of false-positive 
results. Recent reports have suggested that substantial 
numbers of false-positive results could occur in large- 
scale testing situations,6T7 and that these tests may have 
a poor positive predictive value when testing pregnant 
women.* Consequently, the use of HIV confirmatory 
assays such as Western blot (WB) or the indirect fluo- 
rescent assay in testing algorithms is considered the 
standard of care for diagnosing true infection and for 
the re-entry of ELISA-reactive individuals into the 
blood donor pool. However, current confirmatory assays 
are expensive, cumbersome to perform, require skilled 
laboratory staff to perform and correctly interpret results, 
and do not allow for rapid turnaround time for results. 
Advances in the performance characteristics of rapid 
tests, improvement in their accuracy, and the availability 
of multiple recombinant and synthetic peptide antigens, 
impart rapid assays with a potential to simulate WB 
assays, line immunoassays (LIAs),” or recombinant im- 
munoblot assays (RIBAs),‘a which incorporate separated 
antigens or distinct artificially produced antigens to 
identify specific antibodies to HIV. Accordingly, multiple 
specific antigens can be applied to membranes in a rapid 
test format, allowing for the differentiation of antibody 
reactivity. The three antigens of diagnostic significance 
in a WB are ~24, gp41, and gp120/160.11 We report on 
an assessment of a rapid HIV confirmatory assay which 
incorporates separate HIV antigens of diagnostic signi- 
ficance, and discuss the advantages and applications of 
its use. 
METHODS 
archived specimens from five international locations 
(Ivory Coast, Trinidad, Thailand, Peru, and India). 
Fingerstick whole-blood samples were collected from 
patients attending the AIDS Adolescent Clinic at the 
University of Maryland, Baltimore, and from other 
volunteers after signing an IRB-approved consent form. 
Testing by the rapid confirmatory assay was conducted 
immediately at the site of collection for the fingerstick 
whole-blood samples. All samples were coded and un- 
linked to maintain confidentiality and were kept frozen 
at -20% prior to testing. Table 1 lists the sample cate- 
gories and numbers. 
Samples Tests and testing 
In total, 849 samples, including serum, plasma, 
heparinized whole blood, and fingerstick-derived whole 
blood, were used in the evaluation of the rapid test. 
These consisted of 718 HIV-l WB-confirmed positives, 
31 WB negatives, and 26 HIV-l WB-indeterminate 
samples; all were repeatedly reactive by HIV-l/2 screen- 
ing ELISAs. Twenty of the 718 HIV-l WB-confirmed 
positive samples met the criteria for positivity but did 
not react to all viral antigens. The remaining 698 serum/ 
plasma/whole blood samples exhibited reactivity to all 
viral antigens, i.e. ~18, ~24, ~32, gp41, ~51, ~55, ~65, 
gp120, and gp160. Fingerstick whole-blood samples 
(n=20) were obtained from clinically confirmed HIV- 
positive (n =10) and HIV-uninfected individuals (n =lO). 
In addition, 65 of the 849 samples had venipuncture 
whole-blood pairs. The analytic sensitivity of the rapid 
test was assessed using 74 samples from 13 serocon- 
version panels (Boston Biomedica, Inc., Bridgewater, 
MA, USA; BioClinical Partners, Inc., Franklin, MA, 
USA) and included the following well-characterized 
seroconversion panels: PRB-904, PRB-916, PRB-924, 
PRB-929, PRB-931, PRB-935, PRB-936, PRB-937, PRB- 
939, PRB-940, PRB-943, PRB-944, and donor 68106. 
Finally, a reproducibility investigation was conducted 
using three samples tested in replicates of five over a 
4-day period, and 99 samples which were tested at two 
different time points. 
The Quix HIV-l Rapid Antibody Identification Test 
(Guardian Scientific, Inc., Columbia, MD, USA) is a 
5-min, in vitro qualitative diagnostic assay designed to 
detect antibodies to individual proteins of HIV-l in 
whole-blood, serum, and plasma samples. Its intended 
use is to confirm the presence of antibodies to HIV-l in 
specimens found to be repeatedly reactive by screening 
assays such as enzyme immunoassays or rapid tests. 
The Quix HIV-l Rapid Antibody Identification Test 
incorporates one HIV recombinant protein corres- 
ponding to the core protein ~24, and four synthetic 
peptides from the immunodominant regions of the 
envelope proteins gp41 and gp120. These proprietary 
antigens are immobilized on a test membrane as three 
distinct spots to allow the characterization of an 
individual’s immune response to the three specific viral 
antigens. 
Serum and plasma samples were obtained from 
the Clinical Immunology Laboratory at the University 
of Maryland Medical System in Baltimore and from 
The Quix HIV-l Rapid Antibody Identification Test 
consists of a disposable proprietary blood filter 
incorporated into a test cartridge. Following the addition 
of sample, the immobilized antigens on a porous mem- 
brane within the test device capture specific antibodies 
to HIV-l. After a wash step to remove nonspecific 
proteins, the presence of antibodies is revealed by the 
addition of a protein A-colloidal gold conjugate which 
binds to the adsorbed HIV antibodies, forming visually 
discernable red spots at the antigen sites on the 
membrane. A procedural control line, containing anti- 
IgG, binds nonspecific human immunoglobulins in the 
test sample; subsequent staining of this control line with 
Table 1. Summary of sample categories and results 
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Sample Category 
Archived HIV-l-positive sera/plasma from the USA 
Archived HIV-l-positive sera, non-USA 
Archived HIV-l-negative sera from the USA 
HIV-1 Western blot-indeterminate samples 
HIV-l-positive fingerstick whole-blood samples 
HIV-l-negative fingerstick whole-blood samples 
Tota I 
Quix, Quix HIV-l Rapid Antibody Identification Test. 
Number tested 
683 
25 
21 
26 
10 
10 
775 
Concordant 
Results by Quix 
683 
25 
17 
24 
10 
10 
769 
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protein A-colloidal gold at this location indicates that 
the test has been performed correctly, that sample has 
been added, and that all reagents are working properly. 
The assay procedure consists of the separate addition 
into the test cartridge of two drops of proprietary buffer, 
one drop of serum, plasma, or whole-blood sample (45- 
50 u,L), and another two drops of the buffer, removal of 
the filter unit, and the addition of two drops of another 
proprietary buffer, two drops of protein A-colloidal gold 
conjugate, and two drops of the buffer. The criterion for 
a positive result by the test is the presence of reactivity 
to any two of the three viral-specific antigens ~24, gp41, 
and gp120. Reactivity is defined as the appearance of a 
distinct red or pink circular spot. The absence of any 
reactivity to all three antigens, or the presence of any 
reactivity to any one of the three antigens of less in- 
tensity than to the corresponding antigens of the negative 
control, is considered a negative result. The presence 
of reactivity at only one of the three antigen sites is 
considered an indeterminate result. The pink or red 
procedural control line must be visible at a position 
above the three antigen sites for a result to be valid. 
Reference screening and confirmatory assays used 
for the evaluation of the Quix HIV-1Rapid Antibody 
Identification Test included the Genetic Systems HIV- 
l/HIV-2 Peptide EIA (Redmond, WA, USA) or the 
Abbott HIVAB HIV-l/HIV-2 (rDNA) EIA (Abbott 
Park, IL, USA), the Abbott HIVAG Monoclonal p24 
EIA, and the Bio-Rad NOVAPATH HIV-l Immunoblot 
Assay (BioRad Laboratories, Hercules, CA, USA). 
All samples were tested with strict adherence to the 
manufacturers’s instructions. For the WB, reactivity to 
two of the three viral-specific antigens ~24, gp41 and 
gp120/160 was classified as a positive result, whereas the 
absence of any reactivity was considered a negative 
result. Any sample exhibiting reactivity which did not 
meet the criteria for a positive or negative result was 
classified as indeterminate. Samples which produced 
discrepant results between the reference WB assay and 
the Quix HIV-l Rapid Antibody Identification Test 
were retested in duplicate by the rapid assay, and 
2/3 concordant results were considered definitive. This 
retesting was performed only to be confident that a 
technical error had not occurred which would falsely 
bias the true reactivity of the test being evaluated. 
When results were still discordant after repeat testing by 
the rapid test, a WB was again performed. Persistently 
discordant samples were further tested by the Abbott 
HIVAG monoclonal p24 EIA. A positive p24 antigen 
EIA result constituted a final classification of positive 
for that sample, while a negative p24 antigen result could 
not be used as a definitive result. 
For the purpose of determining analytic sensitivity, 
results obtained with the Quix HIV-l Rapid Antibody 
Identification Test were compared to those obtained by 
the providers of the seroconversion panels using the 
Bio-Rad NOVAPATH HIV-l Immunoblot Assay as the 
reference. Qualitative results by each test for each of 
the bleeds were compared. Also, reactions were graded 
from l+ (weak) to 4f (strong) in order to give some 
insight into the intensity of reactions; +/- reactions 
(possible reactivity) were noted but did not constitute a 
positive result for that antigen. 
Precision and reproducibility of the Quix HIV-l 
Rapid Antibody Identification Test were assessed using 
two methods: (1) three samples (strong HIV-l positive, 
weak HIV-l positive, and HIV negative) were each 
tested in replicates of five (precision) on 4 consecutive 
days (reproducibility) using the same lot of reagents and 
test cartridges to determine the intra-lot reproducibility 
of results, and (2) 99 samples were tested using two 
different lots of reagents and cartridges at different time 
periods to determine the inter-lot reproducibility of the 
assay. 
RESULTS 
Of the 775 different samples, excluding the sero- 
conversion panels, the Quix HIV-l Rapid Antibody 
Identification Test exhibited an overall qualitative 
concordance with WB of 99.2% (769/775). All WB- 
confirmed positive samples were also confirmed by the 
Quix rapid assay, yielding a 100% (718/718) sensitivity 
for the correct identification of positives. For 698 of 
these positives, the WB had exhibited reactivity to all 
viral antigens; the rapid assay showed reactivity to all 
three of its antigens. Of the remaining 57 samples, 31 
were WB negative, of which the rapid assay correctly 
classified 27 samples; it produced four indeterminant 
results, showing a 1+ reactivity only to the p24 antigen 
with two sera and reactivity only to gp41 with two sera 
(l+ reactions). Twenty-six of the 57 samples were WB 
indeterminant, of which one produced a negative result 
and another a positive result (l+ p24 and l+ gp41) by 
the rapid confirmatory assay. Of particular note, this 
latter sample exhibited a suspicious profile by WB; that 
is, it showed +/- reactions to ~32, ~65, and gp160, but 
could not be resolved by p24 or HIV-2 testing. This 
resulted in a concordance of 92.3% for the rapid con- 
firmatory assay as compared to the WB with indeterminant 
samples. Five of these total six discordant samples pro- 
duced negative results for the presence of p24 antigen, 
while one had insufficient volume for testing. These 
samples were not tested for the presence of HIV RNA, 
because they were serum rather than plasma samples (as 
recommended), and had not been processed as required 
by the manufacturer of our test kits for RNA testing 
(plasma separation within 6 h). Table 1 shows the results 
for each category of samples, Table 2 illustrates the 
comparison of results by sample status, and Table 3 
shows the reactions of the six samples which produced 
discordant results between the WB and the Quix HIV-l 
Rapid Antibody Identification Test. 
For the 13 seroconversion panels, the Quix HIV-1 
Rapid Antibody Identification Test exhibited identical 
results to those of the Bio-Rad HIV-l WB assay in five 
panels (panels PRB 916,929,931,937, and 944), and had 
a 1 + or greater reactivity at least one bleed earlier than 
the WB assay in five panels (panels PRB 904,939,940, 
943, and donor 68106); in three panels, the rapid test 
produced reactivity one bleed later than did the WB 
assay (panels PRB 924,935, and 936). For the panels in 
which discordance occurred, reactivity to the different 
antigens fluctuated fairly equally by the two tests for 
reactivity to ~24, or to the envelope antigens gp42 or 
gp120/160; that is, there were no consistent differences 
by either of the tests. Similarly, when comparing 
quantitative reactivity to each antigen by each test near 
the time of seroconversion in panels where discordance 
was observed, results were equally variable (+/- or 1+) 
for each of the tests. In two panels (68106 and PRB940), 
the rapid test exhibited a final positive result one or two 
bleeds prior to the WB, while the WB was positive prior 
to the rapid assay in one panel (PRB935). A comparison 
of reactivity of the two tests using seroconversion panels 
is shown in Table 4. 
When assessing the ability of the Quix HIV-l Rapid 
Antibody Identification Test to produce identical results 
with the same lot of reagents upon repeat testing, there 
was 100% reproducibility when testing three samples 
over a 4-day period, and 100% precision when testing 
samples in replicates of five on each of those days. 
Furthermore, when 99 samples were tested using two 
different lots of reagents, only two samples had 
reactivities which resulted in a change of classification 
between the two time periods. In one sample, the 
difference was produced by a +I- reaction versus a 
negative result to the p24 antigen only.The other sample 
produced a l+ reaction versus a negative reaction to the 
Table 2. Comparison of the rapid test results with the Western 
blot based on sample status 
Quix Quix Quix 
Sample Status Positive Negative indeterminate Total 
WB positive 718 0 0 718 
WB negative 0 27 4 31 
WI3 indeterminate 1 1 24 26 
Total 719 28 28 775 
WE, Western blot; Quix, Quix HIV-1 Rapid Antibody Identification Test. 
Table 3. Specific results of six discordant samples 
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p24 antigen only. These two samples, therefore, had 
changes in classification from indeterminate to negative; 
the Western blot results for these samples were indeter- 
minate (+-I- reactions to ~18, p24 and ~31) and negative, 
respectively. 
Twenty whole-blood samples collected by finger- 
stick from 10 known HIV-positive individuals and from 
10 healthy HIV-negative persons produced the expected 
results by the Quix HIV-l Rapid Antibody Identifica- 
tion Test. Reactions were clear and similar to those pro- 
duced when testing fresh or archived samples. Finally, 
the Quix Rapid Antibody Identification Test produced 
the expected and required reaction at the control line in 
all samples, indicating that the procedure was performed 
correctly and that each sample had been added. 
DISCUSSION 
Diagnostic tests for the detection of HIV infection have 
evolved from the classical ELISA and WB tests to new 
technologies and testing strategies that offer advantages 
in a variety of testing situations. Among the advances 
are: HIV screening and confirmatory tests using saliva,‘* 
urine,13 and whole blood collected on filter paper,14 
rapid tests which use serum, saliva, or whole blood,‘“-l7 
fourth-generation screening tests which detect HIV 
antibody and antigen simultaneously,18-20 the routine 
use of tests to detect p24 antigen21 or viral nucleic acids,22 
and sensitive/less sensitive testing strategies23,24 which 
can be used to estimate the incidence of infection in 
order to target the most at-risk populations for imple- 
mentation of intervention strategies. Furthermore, 
molecular tests were introduced which have the 
potential to quantify viral load,25 identify the genotype 
of isolates,26 and measure anti-drug resistance.27 Newer 
tests also incorporate additional antigens in order to 
detect escape variants of HIV? and some tests can 
actually identify the specific group or clade of HIV-1.2’,30 
Alternative testing algorithms,3l including alternative 
confirmatory strategies using rapid assays,3 can result in 
cost and time savings, thereby addressing important 
issues for developing countries. 
The Quix HIV-l Rapid Antibody Identification Test 
represents a new advance in HIV diagnostics and is the 
first such rapid assay developed specifically for the 
purpose of confirming HIV infection. Only one pub- 
Sample Final result by Quix Abbott p24 Ag Final sample status 
No. ID ~24 gP4 7 gpl20 EIA result WB Quix Complete WB band profile 
1 HIV 1757 1+ - N N I No bands 
2 HIV 1764 1+ - N I No bands 
3 HIV 1828 +I- 1+ - QNNS N I No bands 
4 HIV 1899 1+ 1-t N I P 
5 HIV 2003 
p32(+1-),p65(+/-),gp160(+/-) 
- - N I N 
6 HIV 2151 +I- 1+ - 
~65(-)~ 
N N I No bands 
N, negative; P. positive; p, protein; gp, glycoprotein; I, indeterminate; +/-, equivocal; WB, Western blot; Ag, antigen; Quix, Quix HIV-l Rapid Antibody 
Identification Test; QNS, quantity not sufficient. 
aNonspecific band(s) near the indicated protein. 
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lished report suggests the use of a single rapid test The results of the Quix HIV-l Rapid Antibody 
(Genie, BioRad, CA, USA) as a confirmatory strategy,32 Identification Test were compared against those of an 
but this study had a sample size of only 50 positive FDA-licensed WB assay with the objective of deter- 
samples, the test incorporates only gp41 of HIV-l, and mining concordance for the correct identification of 
the test was not specifically designed as a confirmatory antibodies in serum or whole blood of truly infected 
test. However, we are aware of another simple, semi- individuals. The distribution of test samples was chosen 
rapid confirmatory test (Bionor HIV-l & 2 Test, Bionor to simulate the population normally tested by our WB 
AS, Gulset, Norway) which has demonstrated excellent algorithm; that is, all samples are ELISA positive, 
preliminary results in our laboratory (N. T. Constantine with the majority (93%) being WB positive, 3% being 
and E Ketema, unpublished observation). indeterminate, and 4% being negative. The test accom- 
Table 4. Comparison of the reactivity of the Quix rapid test with Western blot using seroconversion panels 
Panel no. Days since 
No. (Member ID) first blood 
Western blot (WB) 
band pattern 
(Bio-Rad) WB reactivity Quix reactivity 
WB Quix 
result result 
1 PRB 904-02 21 
PRB 904-03 49 
PRB 904-04 92 
2 PRB 916-04 15 
PRB 916-05 30 
3 PRB 924-06 33 
PRB 924-07 35 
PRB 924-08 40 
4 PRB 929-06 25 
PRB 929-07 28 
5 PRB 931-06 28 
PRB 931-07 33 
PRB 931-08 35 
6 PRB 936-06 19 
PRB 936-07 21 
7 PRB 937-01 0 
PRB 937-02 7 
PRB 937-03 9 
PRB 937-04 14 
PRB 937-05 16 
PRB 937-06 21 
8 PRB 939(E)-07 21 
PRB 939(E)-08 23 
PRB 939(E)-09 103 
9 PRB 943-05 
PRB 943-06 
PRB 943-07 
10 PRB 944-04 
PRB 944-05 
11 6810649 
68106 -10 
68106 -11 
68106 -12 
12 PRB 935-06 
PRB 935-07 
13 PRB 940-05 
PRB 940-06 
PRB 940-07 
PRB 940-08 
14 
19 
21 
9 
14 
29 
36 
38 
49 
28 
43 
18 
22 
25 
29 
No bands 
No bands 
~18. ~24. gp4l(f). ~55, p65(f), 
gpl20. gp160 
No bands 
~24, gp4l(vf), gplZO(f), gp160 
No bands 
~24 
~24 
No bands 
~24 
No bands 
~24. gpl6Wfl 
~24, ~55. gp160 
No bands 
~18 
No bands 
No bands 
No bands 
No bands 
No bands 
No bands 
No bands 
No bands 
~18, ~24. ~31, gp41, ~51. ~55. 
~65, gp12Qgp160 
No bands 
No bands 
~24 
No bands 
~24, ~55 
No bands 
~24 
~24, p55(f) 
~24, pWf)r gp160 
No bands 
~24, gp160 
~24, ~55 
~24, ~55 
plB(f), ~24. ~55. gpl6O(f) 
~18, ~24, ~55. gp160 
~24 gp41 gp120 ~24 
1+ 
1+ 
R 
R 
R 
R 
R 
R 
R 
R 
1+ 
1+ 
1+ 
R 
R 
R 
R 
R 
R 
1+ 
+/- 
R 
R 
- 
R 
- 
+/- 
- 
1+ 
1+ 
1+ 
+/- 
1+ 
3+ 
-+I- 
1+ 
1+ 
1+ 
+/- 
1+ 
1+ 
R 1+ 
CiP4 1 
1+ 
2+ 
3+ 
+I- 
1+ 
3+ 
4+ 
1+ 
1+ 
2+ 
1+ 
1+ 
1+ 
2+ 
57PlJO 
1+ 
1+ 
1+ 
- 
2+ 
- 
+/- 
+/- 
- 
1+ 
N 
N 
P 
N 
P 
N 
I 
I 
N 
I 
N 
I 
P 
N 
I 
N 
N 
N 
N 
N 
N 
N 
N 
P 
N 
N 
I 
N 
I 
N 
I 
I 
P 
N 
P 
I 
I 
I 
P 
N 
I 
P 
N 
P 
N 
N 
I 
N 
I 
N 
I 
P 
N 
N 
N 
N 
N 
N 
N 
N 
N 
I 
P 
N 
I 
I 
N 
I 
N 
I 
P 
P 
N 
I 
I 
P 
P 
P 
Quix, Quix HIV-1 Rapid Antibody identification Test; p, protein; gp, glycoprotein; P, positive; N, negative; f, faint; vf, very faint; R, reactive; +I- or 
I, indeterminate; WB, Western blot. 
Note: All panels were verified as being from truly seroconverting individuals by testing with additional tests (other Western blots and/or PCR); panels 
PRB 924, 929, 937, 943 and 944 did not exhibit full seroconversion in this evaluation, but were confirmed seroconversion panels as determined by 
Boston Biomedica, Inc. (BBI). 
Only bleeds near the seroconversion time are included in the table (earlier and later bleeds where the Quix and Western blot assays produced identical 
results are not shown). 
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plished the goal for which it was designed: the sensitivity 
for confirming infection was 100% with HIV-l WB- 
confirmed positive samples. The Quix rapid test was also 
presumably capable of detecting HIV non-B clades, as 
was evidenced by the correct classification of 25 HIV- 
positive samples from geographic areas where non-B 
clades predominate. The Quix rapid test showed a 
concordance of 92% (24/26) with the WB test when 
testing samples which were classified as indeterminant 
by WB. We could not, however, conclusively rule out 
these samples as being from truly infected individuals. 
One sample which was repeatedly reactive by the Quix 
rapid assay and the ELISA, and exhibited a suggestive 
WB profile (+/- reactions to ~32, ~65, and gp160), could 
not be resolved by the p24 antigen assay. Conversely, 
one sample which was classified as indeterminant by the 
WB, based on reactivity to a non-viral specific com- 
ponent near ~65, was negative by the Quix rapid test and 
the p24 antigen assay, suggesting that this sample may 
have been from a noninfected person. There were four 
samples which were indeterminate by the Quix HIV-l 
Rapid Antibody Identification Test because of reactivity 
to p24 or gp41, but which were classified as negative by 
WB. Discordant results (indeterminate versus negative) 
by different WB assays are not uncommon (N. T. 
Constantine and E Ketema, unpublished observations), 
and discordant results (indeterminate versus positive) 
by WB can be noted when testing seroconversion 
panels. 33 Furthermore, WB assays may be negative 
during early seroconversion while screening tests are 
reactive.33 Therefore, it is difficult to determine which 
test is yielding the most accurate results. Testing for p24 
antigen did not provide any useful information, and 
RNA testing for resolution could not be performed. 
We did not evaluate the specificity of the Quix 
rapid confirmatory test using HIV-negative samples 
(screening test negatives), because it is well known that 
confirmatory assays should not be used in a screening 
mode. Such specificity studies can only be accomplished 
using ELISA-positive samples that are subsequently 
found to be false positives. Our evaluation used only 
ELISA-positive samples, which represent the same 
sample group that should be tested by confirmatory 
assays. Thus, an assessment of the utility of a new con- 
firmatory test must be performed in comparison with 
reference confirmatory assays on samples targeted for 
confirmatory testing. It would not be appropriate to 
evaluate the specificity of a confirmatory assay using 
ELISA-negative samples. 
For the purpose of looking at the concordance of 
the Quix HIV-l Rapid Antibody Identification Test with 
the WB, a large number of seroconversion panels was 
used. Although there were slight differences between 
the two assays qualitatively and quantitatively when 
testing the seroconversion panels, they were comparable 
in their ability to detect early infection; that is, each 
assay exhibited a similar ability to detect early infection 
with several panels, a variability that is also common 
between different WB assays. Because the purpose of 
a confirmatory assay is to detect established infection, 
slight differences in reactivity during the seroconversion 
period are not unexpected or worrying. The Quix HIV- 
1 Rapid Antibody Identification Test produced reactive 
results as early as, or earlier than, the WB in a majority 
of panels. 
The rapid test performed excellently with finger- 
stick blood specimens, although our sample size was too 
small (n=20) to allow us to draw definitive conclusions; 
however, these preliminary results indicate a potential 
for use with this testing medium. The use of fingerstick 
specimens has several advantages, including cost savings 
based on the elimination of blood-drawing supplies, the 
need for phlebotomists, and the need to discard blood 
units, which are drawn prior to testing in many develop- 
ing countries,34 as well as being applicable in facilities 
where venipuncture is not feasible. The ability of this 
rapid HIV confirmatory test to perform successfully 
with fingerstick specimens is not surprising, since recent 
reports have shown accurate results of HIV rapid 
screening tests when testing blood collected by finger- 
stick.” 
It is clear that a rapid confirmatory assay has 
important utility, particularly with the availability of 
successful therapeutic strategies, which should be 
initiated within 2 h of exposure, i.e. for occupational 
exposure4 or as soon as possible prior to delivery for the 
interruption of vertical transmission from women. in 
labor.5 In these applications, it is desirable to institute 
therapy only in truly infected individuals; however, we 
have noted an almost 1% false-positive result rate with 
the SUDS HIV-l rapid test in our institution, sometimes 
resulting in therapy that was inappropriately admini- 
stered based on the rapid screening test result, because 
some individuals were found subsequently to be 
uninfected (unpublished observations). Translating this 
rate to the large number of occupational exposure cases 
and women in labor without known HIV status, it is 
not unreasonable to expect thousands of false-positive 
results and inappropriate institution of therapy. Also, 
rapid tests have substantial utility when used in public 
health clinics, where a large number of positive in- 
dividuals never return for their initial screening test 
results6 and a large number of positive individuals who 
do return still require confirmatory testing. Even when 
a rapid HIV screening test is performed in this latter 
case, persons with reactive results would still be required 
to revisit clinics following testing of their samples by 
confirmatory assays, which usually require days to weeks. 
Furthermore, confirmatory assays are generally not used 
in developing countries, because they are expensive, and 
instrumentation often cannot be supported, Conse- 
quently, alternative confirmatory strategies have been 
sought and are recommended by the World Health 
Organization in certain testing situations.31 These cost- 
saving strategies include the use of two rapid HIV 
assays, two ELISAs, or a combination of both tests 
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performed in tandem. For these reasons, and in the 
many testing facilities which use rapid assays because of 
the absence of stable electricity or the unavailability of 
instrumentation, a rapid confirmatory assay would offer 
more effective testing. 
Our evaluation of this new-generation rapid HIV 
test, capable of confirming HIV infection, shows proof 
of principle that a confirmatory assay can be successfully 
constructed in a rapid test configuration. This is not 
surprising, because the test principle and antigens are 
similar to the widely used LIA and RIBA tests, and 
because rapid HIV tests have been shown to be accurate. 
We conclude that the Quix HIV-l Rapid Antibody 
Identification Test, a 5-min confirmatory assay for 
correctly classifying HIV infection, has demonstrated 
the ability to accurately confirm HIV-l infection on 
samples which have been found to be reactive by HIV 
screening tests. However, further studies should be 
conducted to assess this assay’s specificity by testing a 
large number of samples which are verified to have 
false-positive results by screening tests. 
Our present study did not evaluate this rapid con- 
firmatory test’s ability to replace HIV screening assays, 
but rather evaluated it as an alternative (after using a 
screening test) to existing confirmatory tests, which are 
more rigorous to perform, more expensive, and less 
applicable in developing countries. The Quix HIV-l 
Rapid Antibody Identification Test exhibits acceptable 
reproducibility, is equivalent to FDA-licensed WB assays 
in analytic sensitivity, has the potential to use fingerstick 
blood, and can provide rapid turnaround time for results. 
Although this rapid confirmatory assay has a number of 
important applications, the most important uses are in 
public health clinics, where client return rates are less 
than desirable, and for occupational exposure cases 
or for women in labor, where the use of antiretroviral 
therapy may be instituted appropriately. In these 
instances, a rapid confirmatory assay could be used 
following repeatedly reactive results by a rapid screen- 
ing test to increase the predictive value of a reactive 
result with respect to it being from a truly infected 
person, while yielding final results in a much shorter 
time than current HIV-testing algorithms that use WB 
assays. 
Thus, after 15 years of evolution of HIV diagnostics, 
new tests with attractive features continue to be intro- 
duced. This addition of a rapid HIV confirmatory test 
offers important advantages that will assist in addressing 
several of the outstanding issues that are important for 
effective testing with appropriate counseling, and the 
correct institution of treatment in a clinically relevant 
time frame. 
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